Treatment of cytomegalovirus infections beyond acute disease to improve human health

References

• Rowe WP, Hartley JW, Waterman S et al. Cytopathogeneic agent resembling human salivary gland virus recovered from tissue cultures of human adenoids. Proc. Soc. Exp. Biol. Med. 92, 418–424 (1956).
   PubMed Web of Science ®Google Scholar
• Klemola E, Kaariainen L. Cytomegalovirus as a possible cause of a disease resembling infectious mononucleosis. Br. Med. J. 2, 1099–1102 (1965).
   PubMed Web of Science ®Google Scholar
• Kaariainen L, Klemola E, Paloheimo J. Rise of cytomegalovirus antibodies in an infectious-mononucleosis-like syndrome after transfusion. Br. Med. J. 1, 1270–1272 (1966).
   PubMed Web of Science ®Google Scholar
• Razonable RR, Hayden RT. Clinical utility of viral load in management of cytomegalovirus infection after solid organ transplantation. Clin. Microbiol. Rev. 26, 703–727 (2013).
   PubMed Web of Science ®Google Scholar
• Razonable RR, Paya CV. Herpesvirus infections in transplant recipients: current challenges in the clinical management of cytomegalovirus and Epstein-Barr virus infections. Herpes 10, 60–65 (2003).
   PubMedGoogle Scholar
• Lonnqvist B, Ringden O, Wahren B, Gahrton G, Lundgren G. Cytomegalovirus infection associated with and preceding chronic graft-versus-host disease. Transplantation 38, 465–468 (1984).
   PubMed Web of Science ®Google Scholar
• Grattan MT, Moreno-Cabral CE, Starnes VA et al. Cytomegalovirus infection is associated with cardiac allograft rejection and atherosclerosis. JAMA 261, 3561–3566 (1989).
   PubMed Web of Science ®Google Scholar
• Potena L, Holweg CT, Chin C et al. Acute rejection and cardiac allograft vascular disease is reduced by suppression of subclinical cytomegalovirus infection. Transplantation 82, 398–405 (2006).
   PubMed Web of Science ®Google Scholar
• Valantine HA, Gao SZ, Menon SG et al. Impact of prophylactic immediate post transplant ganciclovir on development of transplant atherosclerosis: a post hoc analysis of a randomized, placebo-controlled study. Circulation 100, 61–66 (1999).
   PubMed Web of Science ®Google Scholar
• Kalil RS, Hudson SL, Gaston RS. Determinants of cardiovascular mortality after renal transplantation: a role for cytomegalovirus? Am. J. Transplant. 3, 79–81 (2003).
   PubMed Web of Science ®Google Scholar
• Sagedal S, Rollag H, Hartmann A. Cytomegalovirus infection in renal transplant recipients is associated with impaired survival irrespective of expected mortality risk. Clin. Transplant. 21, 309–313 (2007).
   PubMed Web of Science ®Google Scholar
• Potena L, Valantine HA. Cytomegalovirus-associated allograft rejection in heart transplant patients. Curr. Opin. Infect. Dis. 20, 425–431 (2007).
   PubMed Web of Science ®Google Scholar
• Kotton CN. CMV: prevention, diagnosis and therapy. Am. J. Transplant. 13 (Suppl.3), 24–40 (2013).
   PubMedGoogle Scholar
• Soderberg-Naucler C. Does cytomegalovirus play a causative role in the development of various inflammatory diseases and cancer? J. Intern. Med. 259, 219–246 (2006).
   PubMed Web of Science ®Google Scholar
• Fishman JA, Emery V, Freeman R et al. Cytomegalovirus in transplantation - challenging the status quo. Clin. Transplant. 21, 149–158 (2007).
   PubMed Web of Science ®Google Scholar
• Kotton CN, Kumar D, Caliendo AM et al. Updated international consensus guidelines on the management of cytomegalovirus in solid-organ transplantation. Transplantation 96, 333–360 (2013).
   PubMed Web of Science ®Google Scholar
• Söderberg-Nauclér C, Fish K N, Nelson J A. Reactivation of latent human cytomegalovirus by allogeneic stimulation of blood cells from healthy donors. Cell 91, 119–126 (1997).
   PubMed Web of Science ®Google Scholar
• Mendelson M, Monard S, Sissons P, Sinclair J. Detection of endogenous human cytomegalovirus in CD34+ bone marrow progenitors. J. Gen. Virol. 77 (Pt 12), 3099–3102 (1996).
   PubMedGoogle Scholar
• Reeves MB, MacAry PA, Lehner PJ, Sissons JG, Sinclair JH. Latency, chromatin remodeling, and reactivation of human cytomegalovirus in the dendritic cells of healthy carriers. Proc. Natl Acad. Sci. USA 102, 4140–4145 (2005).
   PubMed Web of Science ®Google Scholar
• Murphy E, Yu D, Grimwood J et al. Coding potential of laboratory and clinical strains of human cytomegalovirus. Proc. Natl. Acad. Sci. USA 100, 14976–14981 (2003).
   PubMedGoogle Scholar
• Murphy E, Rigoutsos I, Shibuya T, Shenk TE. Reevaluation of human cytomegalovirus coding potential. Proc. Natl Acad. Sci. USA 100, 13585–13590 (2003).
   PubMedGoogle Scholar
• Mocarski ES, Courcell Tan C. Cytomegalovirus and their replication. In: Fields Virology. Knipe DM, Howley PM (Eds). Lippincott Williams & Wilkins, Philadephia, PA, USA, 2629–2674 (2001).
   Google Scholar
• Stern-Ginossar N, Weisburd B, Michalski A et al. Decoding human cytomegalovirus. Science 338, 1088–1093 (2012).
   PubMed Web of Science ®Google Scholar
• Soderberg-Naucler C. Human cytomegalovirus persists in its host and attacks and avoids elimination by the immune system. Crit. Rev. Immunol. 26, 231–264 (2006).
   Google Scholar
• Powers C, DeFilippis V, Malouli D, Fruh K. Cytomegalovirus immune evasion. Curr. Topics Microbiol. Immunol. 325, 333–359 (2008).
   PubMedGoogle Scholar
• Noriega V, Redmann V, Gardner T, Tortorella D. Diverse immune evasion strategies by human cytomegalovirus. Immunol. Res. 54, 140–151 (2012).
   PubMed Web of Science ®Google Scholar
• Qiu H, Straat K, Rahbar A, Wan M, Soderberg-Naucler C, Haeggstrom JZ. Human CMV infection induces 5-lipoxygenase expression and leukotriene B4 production in vascular smooth muscle cells. J. Exp. Med. 205, 19–24 (2008).
   PubMedGoogle Scholar
• Zhu H, Cong JP, Yu D, Bresnahan WA, Shenk TE. From the Cover: Inhibition of cyclooxygenase 2 blocks human cytomegalovirus replication. Proc. Natl Acad. Sci. USA 99, 3932–3937 (2002).
   PubMed Web of Science ®Google Scholar
• Blankenberg S, Rupprecht HJ, Bickel C et al. Cytomegalovirus infection with interleukin-6 response predicts cardiac mortality in patients with coronary artery disease. Circulation 103, 2915–2921 (2001).
   PubMed Web of Science ®Google Scholar
• Muhlestein JB, Horne BD, Carlquist JF et al. Cytomegalovirus seropositivity and C-reactive protein have independent and combined predictive value for mortality in patients with angiographically demonstrated coronary artery disease. Circulation 102, 1917–1923 (2000).
   PubMed Web of Science ®Google Scholar
• Murayama T, Mukaida N, Khabar KS, Matsushima K. Potential involvement of IL-8 in the pathogenesis of human cytomegalovirus infection. J. Leukoc. Biol. 64, 62–67 (1998).
   PubMedGoogle Scholar
• Murayama T, Ohara Y, Obuchi M et al. Human cytomegalovirus induces interleukin-8 production by a human monocytic cell line, THP-1, through acting concurrently on AP-1- and NF-kappaB-binding sites of the interleukin-8 gene. J. Virol. 71, 5692–5695 (1997).
   PubMed Web of Science ®Google Scholar
• Penfold ME, Dairaghi DJ, Duke GM et al. Cytomegalovirus encodes a potent alpha chemokine. Proc. Natl Acad. Sci. USA 96, 9839–9844 (1999).
   PubMedGoogle Scholar
• Papadakis KA, Tung JK, Binder SW et al. Outcome of cytomegalovirus infections in patients with inflammatory bowel disease. Am. J. Gastroenterol. 96, 2137–2142 (2001).
   PubMed Web of Science ®Google Scholar
• Hansson GK, Libby P. The immune response in atherosclerosis: a double-edged sword. Nat. Rev. Immunol. 6, 508–519 (2006).
   PubMed Web of Science ®Google Scholar
• Hansson GK, Robertson AK, Soderberg-Naucler C. Inflammation and atherosclerosis. Annu. Rev. Pathol. 1, 297–329 (2006).
   PubMed Web of Science ®Google Scholar
• Streblow DN, Orloff SL, Nelson JA. Do pathogens accelerate atherosclerosis? J. Nutr. 131, 2798S–2804S (2001).
   Google Scholar
• Simanek AM, Dowd JB, Pawelec G, Melzer D, Dutta A, Aiello AE. Seropositivity to cytomegalovirus, inflammation, all-cause and cardiovascular disease-related mortality in the United States. PLoS ONE 6, e16103 (2011).
   PubMed Web of Science ®Google Scholar
• Roberts ET, Haan MN, Dowd JB, Aiello AE. Cytomegalovirus antibody levels, inflammation, and mortality among elderly Latinos over 9 years of follow-up. Am. J. Epidemiol. 172, 363–371 (2010).
   PubMed Web of Science ®Google Scholar
• Crumpacker CS. Invited commentary: human cytomegalovirus, inflammation, cardiovascular disease, and mortality. Am. J. Epidemiol. 172, 372–374 (2010).
   PubMedGoogle Scholar
• Gredmark-Russ S, Dzabic M, Rahbar A et al. Active cytomegalovirus infection in aortic smooth muscle cells from patients with abdominal aortic aneurysm. J. Mol. Med. 87, 347–356 (2009).
   PubMed Web of Science ®Google Scholar
• Streblow DN, Soderberg-Naucler C, Vieira J et al. The human cytomegalovirus chemokine receptor US28 mediates vascular smooth muscle cell migration. Cell 99, 511–520 (1999).
   PubMed Web of Science ®Google Scholar
• Carlquist JF, Muhlestein JB, Horne BD et al. Cytomegalovirus stimulated mRNA accumulation and cell surface expression of the oxidized LDL scavenger receptor, CD36. Atherosclerosis 177, 53–59 (2004).
   PubMedGoogle Scholar
• Wang D, Li G, Schauflinger M et al. The ULb' region of the human cytomegalovirus genome confers an increased requirement for the viral protein kinase UL97. J. Virol. 87, 6359–6376 (2013).
   PubMedGoogle Scholar
• Cheng J, Ke Q, Jin Z et al. Cytomegalovirus infection causes an increase of arterial blood pressure. PLoS Pathog. 5, e1000427 (2009).
   PubMed Web of Science ®Google Scholar
• Grudzinska MK, Bojakowski K, Soin J et al. RCMV increases intimal hyperplasia by inducing inflammation, MCP-1 expression and recruitment of adventitial cells to intima. Herpesviridae 1, 7 (2010).
   PubMedGoogle Scholar
• Nieboer TE, Spaanderman ME, Bongers MY, Vierhout ME, Kluivers KB. Gynaecologists estimate and experience laparoscopic hysterectomy as more difficult compared with abdominal hysterectomy. Gynecol. Surg. 7, 359–363 (2010).
   PubMedGoogle Scholar
• Soroceanu L, Cobbs CS. Is HCMV a tumor promoter? Virus Res. 157, 193–203 (2011).
   PubMed Web of Science ®Google Scholar
• Michaelis M, Doerr HW, Cinatl J. The story of human cytomegalovirus and cancer: increasing evidence and open questions. Neoplasia 11, 1–9 (2009).
   PubMed Web of Science ®Google Scholar
• Baryawno N, Rahbar A, Wolmer-Solberg N et al. Detection of human cytomegalovirus in medulloblastomas reveals a potential therapeutic target. J. Clin. Invest. 121, 4043–4055 (2011).
   PubMed Web of Science ®Google Scholar
• Bongers G, Maussang D, Muniz LR et al. The cytomegalovirus-encoded chemokine receptor US28 promotes intestinal neoplasia in transgenic mice. J. Clin. Invest. 120, 3969–3978 (2010).
   Google Scholar
• Slinger E, Maussang D, Schreiber A et al. HCMV-encoded chemokine receptor US28 mediates proliferative signaling through the IL-6-STAT3 axis. Sci. Signal. 3, ra58 (2010).
   Google Scholar
• Melnick M, Sedghizadeh PP, Allen CM, Jaskoll T. Human cytomegalovirus and mucoepidermoid carcinoma of salivary glands: Cell-specific localization of active viral and oncogenic signaling proteins is confirmatory of a causal relationship. Exp. Mol. Pathol. 92, 118–125 (2012).
   PubMed Web of Science ®Google Scholar
• Melnick M, Abichaker G, Htet K, Sedghizadeh P, Jaskoll T. Small molecule inhibitors of the host cell COX/AREG/EGFR/ERK pathway attenuate cytomegalovirus-induced pathogenesis. Exp. Mol. Pathol. 91, 400–410 (2011).
   Google Scholar
• Dziurzynski K, Chang SM, Heimberger AB et al. Consensus on the role of human cytomegalovirus in glioblastoma. Neuro Oncol. 14, 246–255 (2012).
   PubMed Web of Science ®Google Scholar
• Dziurzynski K, Wei J, Qiao W et al. Glioma-associated cytomegalovirus mediates subversion of the monocyte lineage to a tumor propagating phenotype. Clin. Cancer Res. 17, 4642–4649 (2011).
   PubMed Web of Science ®Google Scholar
• Straat K, Liu C, Rahbar A et al. Activation of telomerase by human cytomegalovirus. J. Natl Cancer Inst. 101, 488–497 (2009).
   PubMedGoogle Scholar
• Rahbar A, Stragliotto G, Orrego A et al. Low levels of Human Cytomegalovirus infection in glioblastoma multiforme associates with patient survival; a case-control study. Herpesviridae 3, 3 (2012).
   PubMedGoogle Scholar
• Taher C, de Boniface J, Mohammad AA et al. High prevalence of human cytomegalovirus proteins and nucleic acids in primary breast cancer and metastatic sentinel lymph nodes. PLoS ONE 8, e56795 (2013).
   Google Scholar
• Vestergaard BF, Hornsleth A, Pedersen SN. Occurrence of herpes and adenovirus antibodies in patients with carcinoma of the cervix uteri. Measurement of antibodies to herpesvirus hominis (types 1 and 2), cytomegalovirus, EB-virus, and adenovirus. Cancer 30, 68–74 (1972).
   PubMed Web of Science ®Google Scholar
• Geder L, Kreider J, Rapp F. Human cells transformed in vitro by human cytomegalovirus: tumorigenicity in athymic nude mice. J. Natl Cancer Inst. 58, 1003–1009 (1977).
   PubMedGoogle Scholar
• Geder KM, Lausch R, O'Neill F, Rapp F. Oncogenic transformation of human embryo lung cells by human cytomegalovirus. Science 192, 1134–1137 (1976).
   PubMed Web of Science ®Google Scholar
• Speir E, Huang ES, Modali R et al. Interaction of human cytomegalovirus with p53: possible role in coronary restenosis. Scand. J. Infect. Dis. (Suppl.) 99, 78–81 (1995).
   Google Scholar
• Castillo JP, Kowalik TF. Human cytomegalovirus immediate early proteins and cell growth control. Gene 290, 19–34 (2002).
   PubMed Web of Science ®Google Scholar
• Wade M, Kowalik TF, Mudryj M, Huang ES, Azizkhan JC. E2F mediates dihydrofolate reductase promoter activation and multiprotein complex formation in human cytomegalovirus infection. Mol. Cell Biol. 12, 4364–4374 (1992).
   PubMedGoogle Scholar
• Song YJ, Stinski MF. Effect of the human cytomegalovirus IE86 protein on expression of E2F-responsive genes: a DNA microarray analysis. Proc. Natl Acad. Sci. USA 99(5), 2836–2841 (2002).
   PubMedGoogle Scholar
• Poma EE, Kowalik TF, Zhu L, Sinclair JH, Huang ES. The human cytomegalovirus IE1-72 protein interacts with the cellular p107 protein and relieves p107-mediated transcriptional repression of an E2F-responsive promoter. J. Virol. 70, 7867–7877 (1996).
   PubMedGoogle Scholar
• E X, Pickering MT, Debatis M et al. An E2F1-mediated DNA damage response contributes to the replication of human cytomegalovirus. PLoS Pathog. 7, e1001342 (2011).
   Google Scholar
• Esteki-Zadeh A, Karimi M, Straat K et al. Human cytomegalovirus infection is sensitive to the host cell DNA methylation state and alters global DNA methylation capacity. Epigenetics 7, 585–593 (2012).
   PubMed Web of Science ®Google Scholar
• Maussang D, Langemeijer E, Fitzsimons CP et al. The human cytomegalovirus-encoded chemokine receptor US28 promotes angiogenesis and tumor formation via cyclooxygenase-2. Cancer Res. 69, 2861–2869 (2009).
   PubMed Web of Science ®Google Scholar
• Maussang D, Verzijl D, van Walsum M et al. Human cytomegalovirus-encoded chemokine receptor US28 promotes tumorigenesis. Proc. Natl Acad. Sci. USA 103, 13068–13073 (2006).
   PubMed Web of Science ®Google Scholar
• Cinatl JJr, Kotchetkov R, Scholz M et al. Human cytomegalovirus infectiondecreases expression of thrombospondin-1 independent of the tumor suppressor protein p53. Am. J. Pathol. 155, 285–292 (1999).
   PubMedGoogle Scholar
• Caposio P, Orloff SL, Streblow DN. The role of cytomegalovirus in angiogenesis. Virus Res. 157, 204–211 (2011).
   PubMed Web of Science ®Google Scholar
• Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 144, 646–674 (2011).
   PubMed Web of Science ®Google Scholar
• Rahbar A, Orrego A, Peredo I et al. Human cytomegalovirus infection levels in glioblastoma multiforme are of prognostic value for survival. J. Clin. Virol. 57, 36–42 (2013).
   PubMed Web of Science ®Google Scholar
• Torres HA, Kontoyiannis DP, Aguilera EA et al. Cytomegalovirus infection in patients with lymphoma: an important cause of morbidity and mortality. Clin. Lymphoma Myeloma 6, 393–398 (2006).
   PubMedGoogle Scholar
• Wolmer-Solberg N, Baryawno N, Rahbar A et al. Frequent detection of human cytomegalovirus in neuroblastoma: A novel therapeutic target? Int. J. Cancer 10, 2351–2361 (2013).
   Google Scholar
• Hadaczek P, Ozawa T, Soroceanu L et al. Cidofovir: a novel antitumor agent for glioblastoma. Clin. Cancer Res. (2013) (Epub ahead of print)
   PubMedGoogle Scholar
• Stragliotto G, Rahbar A, Solberg NW et al. Effects of valganciclovir as an add-on therapy in patients with cytomegalovirus-positive glioblastoma: a randomized, double-blind, hypothesis-generating study. Int. J. Cancer 133, 1204–1213 (2013).
   PubMed Web of Science ®Google Scholar
• Soderberg-Naucler C, Rahbar A, Stragliotto G. Survival in patients with glioblastoma receiving valganciclovir. N. Engl. J. Med. 369, 985–986 (2013).
   PubMed Web of Science ®Google Scholar
• Hodson EM, Jones CA, Webster AC et al. Antiviral medications to prevent cytomegalovirus disease and early death in recipients of solid-organ transplants: a systematic review of randomised controlled trials. Lancet 365, 2105–2115 (2005).
   PubMed Web of Science ®Google Scholar
• Fielding K, Koba A, Grant AD et al. Cytomegalovirus viremia as a risk factor for mortality prior to antiretroviral therapy among HIV-infected gold miners in South Africa. PLoS ONE 6, e25571 (2011).
   PubMed Web of Science ®Google Scholar
• Bristow BN, O'Keefe KA, Shafir SC, Sorvillo FJ. Congenital cytomegalovirus mortality in the United States, 1990–2006. PLoS Negl. Trop. Dis. 5, e1140 (2011).
   Google Scholar
• Malm G, Grondahl EH, Lewensohn-Fuchs I. Congenital cytomegalovirus infection: a retrospective diagnosis in a child with pachygyria. Pediatr. Neurol. 22, 407–408 (2000).
   PubMed Web of Science ®Google Scholar
• Swanson EC, Schleiss MR. Congenital cytomegalovirus infection: new prospects for prevention and therapy. Pediatr. Clin. North Am. 60, 335–349 (2013).
   PubMed Web of Science ®Google Scholar
• Tsai WP, Chen MH, Lee MH et al. Cytomegalovirus infection causes morbidity and mortality in patients with autoimmune diseases, particularly systemic lupus: in a Chinese population in Taiwan. Rheumatol. Int. 32, 2901–2908 (2012).
   PubMed Web of Science ®Google Scholar
• Nakase H, Matsumura K, Yoshino T, Chiba T. Systematic review: cytomegalovirus infection in inflammatory bowel disease. J. Gastroenterol. 43, 735–740 (2008).
   PubMed Web of Science ®Google Scholar
• Gkrania-Klotsas E, Langenberg C, Sharp SJ, Luben R, Khaw KT, Wareham NJ. Seropositivity and higher immunoglobulin g antibody levels against cytomegalovirus are associated with mortality in the population-based European prospective investigation of cancer-nor folk cohort. Clin. Infect. Dis. 56, 1421–1427 (2013).
   PubMed Web of Science ®Google Scholar
• Wang GC, Kao WH, Murakami P et al. Cytomegalovirus infection and the risk of mortality and frailty in older women: a prospective observational cohort study. Am. J. Epidemiol. 171, 1144–1152 (2010).
   PubMedGoogle Scholar
• Savva GM, Pachnio A, Kaul B et al. Cytomegalovirus infection is associated with increased mortality in the older population. Aging Cell, 12, 381–387 (2013).
   PubMed Web of Science ®Google Scholar
• Eid AJ, Razonable RR. New developments in the management of cytomegalovirus infection after solid organ transplantation. Drugs 70, 965–981 (2010).
   PubMed Web of Science ®Google Scholar
• Kotton CN, Kumar D, Caliendo AM et al. International consensus guidelines on the management of cytomegalovirus in solid organ transplantation. Transplantation 89, 779–795 (2010).
   PubMed Web of Science ®Google Scholar
• Xu X, Bergman P, Willows T et al. CMV-associated encephalitis and antineuronal autoantibodies–a case report. BMC Neurol. 12, 87 (2012).
   Google Scholar
• Einsele H, Roosnek E, Rufer N et al. Infusion of cytomegalovirus (CMV)-specific T cells for the treatment of CMV infection not responding to antiviral chemotherapy. Blood 99, 3916–3922 (2002).
   PubMed Web of Science ®Google Scholar
• Condie RM, O'Reilly RJ. Prevention of cytomegalovirus infection by prophylaxis with an intravenous, hyperimmune, native, unmodified cytomegalovirus globulin. Randomized trial in bone marrow transplant recipients. Am. J. Med. 76, 134–141 (1984).
   PubMed Web of Science ®Google Scholar
• Vigil KJ, Adachi JA, Chemaly RF. Viral pneumonias in immunocompromised adult hosts. J. Intensive Care Med. 25, 307–326 (2010).
   PubMedGoogle Scholar
• Ruttmann E, Geltner C, Bucher B et al. Combined CMV prophylaxis improves outcome and reduces the risk for bronchiolitis obliterans syndrome (BOS) after lung transplantation. Transplantation 81, 1415–1420 (2006).
   PubMed Web of Science ®Google Scholar
• Sullivan KM, Kopecky KJ, Jocom J et al. Immunomodulatory and antimicrobial efficacy of intravenous immunoglobulin in bone marrow transplantation. N. Engl. J. Med. 323, 705–712 (1990).
   PubMed Web of Science ®Google Scholar
• Asberg A, Humar A, Rollag H et al. Oral valganciclovir is noninferior to intravenous ganciclovir for the treatment of cytomegalovirus disease in solid organ transplant recipients. Am. J. Transplant. 7, 2106–2113 (2007).
   PubMed Web of Science ®Google Scholar
• Valantine HA. Prevention and treatment of cytomegalovirus disease in thoracic organ transplant patients: evidence for a beneficial effect of hyperimmune globulin. Transplant. Proc. 27(Suppl. 1), 49–57 (1995).
   PubMedGoogle Scholar
• Valantine HA, Luikart H, Doyle R et al. Impact of cytomegalovirus hyperimmune globulin on outcome after cardiothoracic transplantation: a comparative study of combined prophylaxis with CMV hyperimmune globulin plus ganciclovir versus ganciclovir alone. Transplantation 72, 1647–1652 (2001).
   PubMed Web of Science ®Google Scholar
• Sullivan KM. Immunomodulation in allogeneic marrow transplantation: use of intravenous immune globulin to suppress acute graft-versus-host disease. Clin. Exp. Immunol. 1, 43–48 (1996).
   Google Scholar
• Avery RK, Marty FM, Strasfeld L et al. Oral maribavir for treatment of refractory or resistant cytomegalovirus infections in transplant recipients. Transplant Infect. Dis. 12, 489–496 (2010).
   PubMed Web of Science ®Google Scholar
• Marty FM, Winston DJ, Rowley SD et al. CMX001 to prevent cytomegalovirus disease in hematopoietic-cell transplantation. N. Engl. J. Med. 369, 1227–1236 (2013).
   PubMed Web of Science ®Google Scholar
• Shapira MY, Resnick IB, Chou S et al. Artesunate as a potent antiviral agent in a patient with late drug-resistant cytomegalovirus infection after hematopoietic stem cell transplantation. Clin. Infect. Dis. 46, 1455–1457 (2008).
   PubMed Web of Science ®Google Scholar
• Efferth T, Ramirez T, Gebhart E, Halatsch ME. Combination treatment of glioblastoma multiforme cell lines with the anti-malarial artesunate and the epidermal growth factor receptor tyrosine kinase inhibitor OSI-774. Biochem. Pharmacol. 67, 1689–1700 (2004).
   PubMed Web of Science ®Google Scholar
• Rothwell PM, Fowkes FG, Belch JF, Ogawa H, Warlow CP, Meade TW. Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials. Lancet 377, 31–41 (2011).
   PubMed Web of Science ®Google Scholar
• Rothwell PM, Wilson M, Elwin CE et al. Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials. Lancet 376, 1741–1750 (2010).
   PubMed Web of Science ®Google Scholar
• Ararat E, Sahin I, Altundag K. Aspirin intake may prevent metastasis in patients with triple-negative breast cancer. Med. Oncol. 28, 1308–1310 (2011).
   PubMedGoogle Scholar
• Moayyedi P, Jankowski JA. Does long term aspirin prevent cancer? BMJ 341, c7326 (2010).
   Google Scholar
• Aspirin as colon cancer treatment? Harvard Health Lett. 35, 3 (2010).
   Google Scholar
• Potter JD. Aspirin and cancer prevention and treatment: are we there yet? Cancer Epidemiol. Biomarkers Prev. 21, 1439–1440 (2012).
   PubMedGoogle Scholar
• Kmietowicz Z. Study finds possible role for aspirin as treatment for colon cancer. BMJ 344, e2988 (2012).
   Google Scholar
• Bruening W, Giasson B, Mushynski W, Durham HD. Activation of stress-activated MAP protein kinases up-regulates expression of transgenes driven by the cytomegalovirus immediate/early promoter. Nucleic Acids Res. 26, 486–489 (1998).
   PubMed Web of Science ®Google Scholar
• Chan G, Nogalski MT, Bentz GL et al. PI3K-dependent upregulation of Mcl-1 by human cytomegalovirus is mediated by epidermal growth factor receptor and inhibits apoptosis in short-lived monocytes. J. Immunol. 184, 3213–3222 (2010).
   PubMedGoogle Scholar
• Andrassy J, Hoffmann VS, Rentsch M et al. Is cytomegalovirus prophylaxis dispensable in patients receiving an mTOR inhibitor-based immunosuppression? a systematic review and meta-analysis. Transplantation 94, 1208–1217 (2012).
   PubMed Web of Science ®Google Scholar
• Jafferji I, Bain M, King C, Sinclair JH. Inhibition of epidermal growth factor receptor (EGFR) expression by human cytomegalovirus correlates with an increase in the expression and binding of Wilms' Tumour 1 protein to the EGFR promoter. J. Gen. Virol. 90(Pt 7), 1569–1574 (2009).
   PubMedGoogle Scholar
• Soroceanu L, Akhavan A, Cobbs CS. Platelet-derived growth factor-alpha receptor activation is required for human cytomegalovirus infection. Nature 455, 391–395 (2008).
   PubMed Web of Science ®Google Scholar
• Horne BD, Muhlestein JB, Carlquist JF et al. Statin therapy interacts with cytomegalovirus seropositivity and high C-reactive protein in reducing mortality among patients with angiographically significant coronary disease. Circulation 107, 258–263 (2003).
   PubMed Web of Science ®Google Scholar
• Chiurchiu S, Calo Carducci FI, Rocchi F et al. Is HCMV vaccine an unmet need? The state of art of vaccine development. Int. J. Immunopathol. Pharmacol. 26, 15–26 (2013).
   PubMedGoogle Scholar